eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img
Home / HCP / Dosing and Switching / Dosing in DVT and PE

ELIQUIS (apixaban) dosing for patients with DVT / PE

Start twice daily, stay twice daily for your patients with DVT / PE1

ELIQUIS indications1

Dose1

 knee-icon

Morning*

 knee-icon

Night*
knee-iconlung-icon

DVT / PE treatment: treatment of DVT and PE in adults

Day 1–7:
10 mg BD

5mgTablet-icon5mgTablet-icon
ELIQUIS 5 mg x2

5mgTablet-icon5mgTablet-icon
ELIQUIS 5 mg x2

Day 8 onwards:
5 mg BD
for at least 3 months†

knee-icon
ELIQUIS 5 mg

knee-icon
ELIQUIS 5 mg
combined-Lung-knee-icon

Prevention of recurrent DVT / PE: prevention of recurrent DVT and / or PE in adults following completion of 6 months of treatment with ELIQUIS 5 mg BD or with another anticoagulant treatment for DVT or PE

2.5 mg BD

knee-icon
ELIQUIS 2.5 mg

knee-icon
ELIQUIS 2.5 mg

The duration of overall therapy should be individualised after careful assessment of the treatment benefit against the risk for bleeding.1

* Tablets shown are not actual size.

† Short duration of treatment (at least 3 months) should be based on transient risk factors (e.g. recent surgery, trauma, immobilisation).1
Diagnosemethoden

Dosing may differ for some patients with renal impairment – please also see recommendations for patients with hepatic impairment1

VIEW DOSING
CONSIDERATIONS FOR
PATIENTS WITH RENAL OR
HEPATIC IMPAIRMENT

ELIQUIS has established efficacy and safety in
DVT / PE1

VIEW DATA FOR ELIQUIS
IN DVT AND PE

View information to assist your daily practice, including adverse reactions, contraindications and interactions

GET PRACTICAL
INFORMATION
Purple information icon ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

Purple information icon ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

BD = Twice Daily   
DVT = Deep Vein Thrombosis   
INR = International Normalised Ratio   
LMWH = Low Molecular Weight Heparin   
NVAF = Non-Valvular Atrial Fibrillation   
PE = Pulmonary Embolism   
VTE = Venous Thromboembolic Events

Not all patients who start on ELIQUIS for acute DVT / PE will stay on ELIQUIS; some acute DVT / PE patients who receive treatment do not require treatment for the prevention of recurrent DVT / PE. Other patients may be prescribed ELIQUIS for the prevention of recurrent VTE after initial treatment for acute DVT / PE with another anticoagulant.1 This is a decision for the prescribing clinician together with patient involvement in the decision-making.

Reference

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.

You may contact our EU Data Protection Officer at EUDPO@BMS.com to exercise any data privacy rights that you may have, as well as to raise any concerns or questions in relation to the handling of your
personal data by Bristol-Myers Squibb Company.

bristol myers squibb logo

© 2020 Bristol-Myers Squibb Pharmaceuticals Limited

All corporate names and logos of BMS and/or of its products are trademarks of Bristol-Myers Squibb Company and are protected by national and international intellectual and industrial property laws. All rights reserved over the content of this website.

Your use of this website is subject to the Legal Notice, the Privacy and Cookie Policy, the Pharmacovigilance Notice and the applicable laws and regulations.

432UK1700313-01
Date of preparation: February 2020